Revolution Medicines reports Q1 2026 results today having become one of the most striking momentum stories in biotech this year. The stock closed at $151.07, up 52% over the past month and 7.5% on the week alone — a run that has compressed short interest and left the Street scrambling to lift price targets.
The sheer velocity of that rally has already done some of the shorts' work for them. Short interest has declined roughly 14% from mid-April highs, now holding at 7.0% of the free float — meaningful for a $31 billion biotech, but no longer building. Cost to borrow remains modest at under 0.5%, and availability is very loose, pointing to an ample lending pool with no squeeze dynamics in play. Options positioning has actually turned more constructive into the print: the put/call ratio dropped to 1.26, running more than a standard deviation below its 20-day average of 1.39. That's a notable shift from the heavily put-skewed readings above 1.7 seen in March and early April, suggesting the market has re-rated its hedging appetite as the stock climbed.
Analysts validated that re-rating with a wave of target increases through April. The Street is broadly bullish — Evercore lifted its target to $200, Stifel to $215, and Needham to $186, all maintaining Buy-equivalent ratings. The consensus target now stands at $177, implying roughly 17% upside from current levels. The bull thesis centres on daraxonrasib's potential in first-line pancreatic cancer, where RVMD claims first-mover advantage in the RAS-addicted tumour space and a US addressable market estimated near $18 billion. Bears point to the Phase 3 trial's dual primary endpoint structure as a high bar, note emerging competition for zoldonrasib in KRASG12D+ NSCLC, and flag the usual clinical-stage risks of regulatory setback and dilutive financing.
The insider picture adds a note of caution worth flagging. CEO Mark Goldsmith sold 120,000 shares on April 15 at roughly $150 — a transaction worth $18 million — right as the stock was approaching current levels. Several other C-suite executives sold smaller tranches through late March and April. Net insider activity over the past 90 days is nonetheless modestly net-positive in share terms, so the sales appear to reflect planned disposals rather than a coordinated exit, but the timing into the rally is visible.
With the stock nearly doubling off its year-to-date lows and short sellers paring exposure rather than adding, today's print will test whether the clinical narrative behind daraxonrasib can sustain a valuation that has already priced in significant optimism.
See the live data behind this article on ORTEX.
Open RVMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
